Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best biotech stocks with high potential. In a report released on October 3, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) and set a price target of $145.00. Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported in its fiscal Q2 2025 results that it used $12.6 million of cash in its operating activities during the three months ended June 30, 2025. T ...